GlassScriptPhysician profile
Alice A Lim
NPI 1912956491
$3,489.49
in general payments reported to CMS, 2019-2025
27 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $653 · 2021: $540 · 2022: $460 · 2023: $557 · 2024: $581 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $786.51 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $658.25 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.15 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $290.94 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $285.31 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Amarin Pharma, INC. | $173.92 | 2019-2023 | |
| Horizon Therapeutics Plc | $129.37 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $126.81 | 2022-2024 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $117.43 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $83.42 | 2020-2021 | |
| Exact Sciences Corporation | $51.18 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $46.33 | 2020-2021 | |
| Abbott Laboratories | $46.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $44.06 | 2019-2024 | Zoryve |
| Corcept Therapeutics | $38.44 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $31.69 | 2023 | Adlarity |
| Merck Sharp & Dohme LLC | $27.82 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $24.36 | 2020 | |
| Pfizer INC. | $24.19 | 2024 | |
| Dexcom, INC. | $22.38 | 2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $18.94 | 2023 | Inspire |
| Althera Pharmaceuticals LLC | $18.38 | 2022 | |
| Linus Health, INC. | $18.20 | 2023 | |
| Redhill Biopharma INC. | $16.14 | 2021 | |
| Antares Pharma, INC. | $14.81 | 2021 | |
| Genentech USA, INC. | $13.14 | 2021 | |
| Esperion Therapeutics, INC. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.